分享新知，自由传播
德国BioNTech公司表示，其新冠疫苗在中国的批准仍然“极其重要”，不过，目前还很难预测中国监管审查的可能结果。
德国BioNTech公司首席商务官Sean Marett在今年在线举行的摩根大通的年度医疗会议上表示：“这是一场与中国监管当局的持续对话。”
他说，任何批准都“很难预测”，并补充说，“中国对我们仍然极其重要，我们正在致力于寻求（审批）”。
该公司最初在去年表示，最早可能于7月在中国大陆获得批准。
在中国，上海复星药业是该公司的合作伙伴。复必泰疫苗已经在中国香港、澳门和台湾使用。
在世界其他地区，德国BioNTech的合作伙伴是美国制药巨头辉瑞公司。
来源：REUTERS；编译：POLARZONE
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |